| Business Summary | | Cygnus
Inc.
develops
and
manufactures
diagnostic
medical
devices,
utilizing
proprietary
technologies
to
satisfy
unmet
medical
needs
cost-effectively.
The
first
such
device
is
a
frequent,
automatic
and
non-invasive
glucose
monitoring
device,
the
GlucoWatch
biographer,
and
enhancements
thereto.
The
Company
believes
that
there
is
an
unmet
need
for
automatic,
frequent
and
non-invasive
glucose
monitoring.
In
an
effort
to
address
this
unmet
need,
the
Company
has
developed
the
GlucoWatch
biographer.
The
system
is
comprised
of
two
components:
a
durable
component
known
as
the
biographer,
and
a
consumable
component
known
as
the
AutoSensor.
The
durable
GlucoWatch
biographer
is
worn
like
a
wristwatch
and
displays
and
stores
current
and
past
glucose
levels
and
trend
data.
The
AutoSensor,
after
calibration
with
a
standard
blood
glucose
monitor,
is
attached
to
the
back
of
the
biographer
and
automatically
extracts
and
measures
glucose
levels
through
intact
skin
every
20
minutes. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Cygnus
Inc.
develops
and
manufactures
diagnostic
medical
services,
utilizing
proprietary
technologies.
Cygnus
currently
focuses
on
glucose
monitoring
devices.
For
the
six
months
ended
6/01,
revenues
totalled
$5.1
million,
up
from
$1
million.
Net
loss
increased
45%
to
$18
million.
Results
reflect
the
inclusion
of
a
milestone
payment
for
the
Company's
GlucoWatch
Biographer,
offset
by
expenses
to
test
and
develop
high-capacity
manufacturing
processes. | More
from
Market Guide: Significant
Developments |
| | | | FY2000
Compensation | | Pay | Exer | |
| John Hodgman, 46 Chairman,
Pres and CEO | $300K | -- | Andre Marion, 65 Vice
Chairman | -- | -- | Craig Carlson, 53 CFO,
Chief Operating Officer, Sr. VP-Fin. | 202K | $68K | Neil Ackerman, Ph.D., 57 Sr.
VP, R&D and Scientific Affiars; CTO | 235K | 227K | Barbara McClung, 46 Sr.
VP, Gen. Counsel, Sec. | 186K | -- | Dollar
amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|